Loading
A phase 2 trial of CC-486 in acute myeloid leukaemia, run by Bristol-Myers Squibb, active and no longer recruiting.
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission is a phase 2 interventional study registered as NCT05413018 by Bristol-Myers Squibb, with 34 participants enrolled, started 2022-08-19 and due to reach its primary completion in 2025-10-31. Interventions recorded: CC-486.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb, Acute myeloid leukaemia and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Shares Bristol Myers Squibb, Acute myeloid leukaemia and the tag pipeline.
Shares Bristol Myers Squibb and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/